CSPC Pharma's SYS6088 Injection Begins Phase I/II Clinical Trial in China for Advanced Solid Tumors

Stock News11-03 18:34

CSPC Pharma (01093) has announced that the Phase I/II clinical trial (SYS6088-001) of SYS6088 Injection, developed by the company for the treatment of advanced solid tumors, has officially commenced at its first research site in China.

The product is a recombinant humanized trispecific antibody targeting programmed death receptor 1 (PD1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). It can specifically bind to PD1 and CTLA4 on the surface of target cell membranes as well as VEGFA in the tumor microenvironment, thereby restoring the killing function of T lymphocytes (T cells) within the tumor microenvironment, inhibiting angiogenesis, and expanding T cells during the immune priming phase, exerting a triple synergistic antitumor effect. The modification of the Fc region reduces the toxicity risk of the product while effectively extending its half-life.

The company received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration in October 2026 and initiated the Phase I clinical trial of the product following approval. The Phase I/II clinical trial now launched is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of the product in patients with advanced solid tumors. Currently, participant recruitment and screening for this clinical trial are being actively advanced.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196948865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-03 18:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196948865","market":"other","top_or_hot":-1,"title":"CSPC Pharma's SYS6088 Injection Begins Phase I/II Clinical Trial in China for Advanced Solid Tumors","media":"Stock News","content":"<p>CSPC Pharma (01093) has announced that the Phase I/II clinical trial (SYS6088-001) of SYS6088 Injection, developed by the company for the treatment of advanced solid tumors, has officially commenced at its first research site in China.<br><br>The product is a recombinant humanized trispecific antibody targeting programmed death receptor 1 (PD1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). It can specifically bind to PD1 and CTLA4 on the surface of target cell membranes as well as VEGFA in the tumor microenvironment, thereby restoring the killing function of T lymphocytes (T cells) within the tumor microenvironment, inhibiting angiogenesis, and expanding T cells during the immune priming phase, exerting a triple synergistic antitumor effect. The modification of the Fc region reduces the toxicity risk of the product while effectively extending its half-life.<br><br>The company received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration in October 2026 and initiated the Phase I clinical trial of the product following approval. The Phase I/II clinical trial now launched is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of the product in patients with advanced solid tumors. Currently, participant recruitment and screening for this clinical trial are being actively advanced.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma's SYS6088 Injection Begins Phase I/II Clinical Trial in China for Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma's SYS6088 Injection Begins Phase I/II Clinical Trial in China for Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-11-03 18:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharma (01093) has announced that the Phase I/II clinical trial (SYS6088-001) of SYS6088 Injection, developed by the company for the treatment of advanced solid tumors, has officially commenced at its first research site in China.<br><br>The product is a recombinant humanized trispecific antibody targeting programmed death receptor 1 (PD1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). It can specifically bind to PD1 and CTLA4 on the surface of target cell membranes as well as VEGFA in the tumor microenvironment, thereby restoring the killing function of T lymphocytes (T cells) within the tumor microenvironment, inhibiting angiogenesis, and expanding T cells during the immune priming phase, exerting a triple synergistic antitumor effect. The modification of the Fc region reduces the toxicity risk of the product while effectively extending its half-life.<br><br>The company received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration in October 2026 and initiated the Phase I clinical trial of the product following approval. The Phase I/II clinical trial now launched is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of the product in patients with advanced solid tumors. Currently, participant recruitment and screening for this clinical trial are being actively advanced.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1951186391.HKD","symbol_name":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","start_time":0,"source_url":"","article_id":"1196948865","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196948865","pubTimestamp":1793702054,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSPC Pharma (01093) has announced that the Phase I/II clinical trial (SYS6088-001) of SYS6088 Injection, developed by the company for the treatment of advanced solid tumors, has officially commenced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","BK1515":"抗疫概念","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","PSYK":"PSYK ETF","BMED":"iShares Health Innovation Active ETF","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","MDTX":"Corgi MediaTek 2x Daily ETF","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","01093":"石药集团","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK1191":"制药","KURE":"KraneShares MSCI All China Health Care Index ETF","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC"},"translate_title":"石药集团SYS6088注射液在中国开展晚期实体瘤I/II期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":1,"IBBJ":1,"MDTX":1,"BMED":1,"IBBQ":1,"01093":1,"PSYK":1},"content_text":"CSPC Pharma (01093) has announced that the Phase I/II clinical trial (SYS6088-001) of SYS6088 Injection, developed by the company for the treatment of advanced solid tumors, has officially commenced at its first research site in China.The product is a recombinant humanized trispecific antibody targeting programmed death receptor 1 (PD1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). It can specifically bind to PD1 and CTLA4 on the surface of target cell membranes as well as VEGFA in the tumor microenvironment, thereby restoring the killing function of T lymphocytes (T cells) within the tumor microenvironment, inhibiting angiogenesis, and expanding T cells during the immune priming phase, exerting a triple synergistic antitumor effect. The modification of the Fc region reduces the toxicity risk of the product while effectively extending its half-life.The company received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration in October 2026 and initiated the Phase I clinical trial of the product following approval. The Phase I/II clinical trial now launched is a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of the product in patients with advanced solid tumors. Currently, participant recruitment and screening for this clinical trial are being actively advanced.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196948865","isCrawlerRequest":true}